Aktienanalyse zu Cullinan Therapeutics Inc (CGEM)CGEMCullinan Therapeutics Inc

Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Cullinan Oncology Inc (CGEM) is a good buy right now, primarily driven by its current price of $14.37, which is significantly lower than analyst price targets of $35 to $47. The stock has shown a strong year-to-date change of +42.00% and a one-year change of +78.29%, suggesting positive momentum. However, the main risk is the negative earnings per share (EPS) forecast of -0.79 for the upcoming quarter, which could impact investor sentiment.